For example, PD-L1 expression measured by immunohistochemistry, the most commonly used biomarker for immune checkpoint inhibitors, is commonly assessed by archive tissue samples for patients with metastatic tumors [48]. This evidence concerns the gene CD274 and metastatic neoplasm.